Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Feb 09, 2022

SELL
$3.43 - $4.65 $1,859 - $2,520
-542 Closed
0 $0
Q3 2020

Nov 12, 2020

BUY
$3.91 - $7.15 $1,630 - $2,981
417 Added 333.6%
542 $2,000
Q4 2018

Feb 08, 2019

BUY
$2.65 - $9.2 $331 - $1,150
125 New
125 $0

Others Institutions Holding DMAC

About DiaMedica Therapeutics Inc.


  • Ticker DMAC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 26,443,100
  • Market Cap $106M
  • Description
  • DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type...
More about DMAC
Track This Portfolio

Track Gables Capital Management Inc. Portfolio

Follow Gables Capital Management Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gables Capital Management Inc., based on Form 13F filings with the SEC.

News

Stay updated on Gables Capital Management Inc. with notifications on news.